Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 4/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506032 | 1.00 | LMNA (0.63) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL20746348 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL20740310 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL20746363 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL21996120 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL25125871 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL20746351 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL20746187 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL20746400 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 | |
| SCHEMBL20746409 | 0.96 | LMNA (0.68) | LMNAOPRM1TSHRTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668957-A1 | FURAN BASED COMPOSITIONS AND METHODS OF MAKING THEREOF | University of Delaware (US) | 2020-06-24 | — | — | EP | claimed |
| WO-2019036663-A1 | FURAN BASED COMPOSITIONS AND METHODS OF MAKING THEREOF | UNIVERSITY OF DELAWARE (US) | 2019-02-21 | — | — | WO | claimed |
| US-20210040055-A1 | FURAN BASED COMPOSITIONS AND METHODS OF MAKING THEREOF | UNIVERSITY OF DELAWARE (US) | 2021-02-11 | — | — | US | disclosed |
| EP-3668957-A1 | FURAN BASED COMPOSITIONS AND METHODS OF MAKING THEREOF | University of Delaware (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036663-A1 | FURAN BASED COMPOSITIONS AND METHODS OF MAKING THEREOF | UNIVERSITY OF DELAWARE (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040055-A1 | FURAN BASED COMPOSITIONS AND METHODS OF MAKING THEREOF | CBR3, CBR1, FPR3 | LMNA 410/4885OPRM1 76/4885TSHR 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.